Federica De Santis

Dr. Federica De Santis

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Federica RinaldiFederica Rinaldi
Federica Rinaldi
Patrizia Nadia HaniehPatrizia Nadia Hanieh
Patrizia Nadia Hanieh
SSSimona Sennato
Simona Sennato
FSFederica De Santis
Federica De Santis
JFJacopo Forte
Jacopo Forte
Maria CarafaMaria Carafa
Maria Carafa
Treatment of pulmonary infections caused by Mycobacterium abscessus are extremely difficult to treat, as this species is naturally resistant to many common antibiotics. Liposomes are vesicular nanocarriers suitable for hydrophilic and lipophilic drug loading, able to deliver drugs to the target site, and successfully used in different pharmaceutical applications. Moreover, liposomes are biocompatible, biodegradable and nontoxic vesicles and nebulized liposomes are efficient in targeting antibacterial agents to macrophages. The present aim was to formulate rifampicin-loaded liposomes (RIF–Lipo) for lung delivery, in order to increase the local concentration of the antibiotic. Unilamellar liposomal vesicles composed of anionic DPPG mixed with HSPC for rifampicin delivery were designed, prepared, and characterized. Samples were prepared by using the thin-film hydration method. RIF–Lipo and unloaded liposomes were characterized in terms of size, ζ-potential, bilayer features, stability and in different biological media. Rifampicin’s entrapment efficiency and release were also evaluated. Finally, biological activity of RIF-loaded liposomes in Mycobacterium abscessus-infected macrophages was investigated. The results show that RIF-lipo induce a significantly better reduction of intracellular Mycobacterium abscessus viability than the treatment with free drug. Liposome formulation of rifampicin may represent a valuable strategy to enhance the biological activity of the drug against intracellular mycobacteria.

6 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
LALucia Henrici De Angelis
Lucia Henrici De Angelis
Noemi PoerioNoemi Poerio
Noemi Poerio
VPVINCENZO DI PILATO
VINCENZO DI PILATO
FSFederica De Santis
Federica De Santis
AAAlberto Antonelli
Alberto Antonelli
Marco Maria D'AndreaMarco Maria D'Andrea
Marco Maria D'Andrea
Phage therapy is now reconsidered with interest in the treatment of bacterial infections. A major piece of information for this application is the definition of the molecular targets exploited by phages to infect bacteria. Here, the genetic basis of resistance to the lytic phage φBO1E by its susceptible host Klebsiella pneumoniae KKBO-1 has been investigated. KKBO-1 phage-resistant mutants were obtained by infection at high multiplicity. One mutant, designated BO-FR-1, was selected for subsequent experiments, including virulence assessment in a Galleria mellonella infection model and characterization by whole-genome sequencing. Infection with BO-FR-1 was associated with a significantly lower mortality when compared to that of the parental strain. The BO-FR-1 genome differed from KKBO-1 by a single nonsense mutation into the wbaP gene, which encodes a glycosyltransferase involved in the first step of the biosynthesis of the capsular polysaccharide (CPS). Phage susceptibility was restored when BO-FR-1 was complemented with the constitutive wbaP gene. Our results demonstrated that φBO1E infects KKBO-1 targeting the bacterial CPS. Interestingly, BO-FR-1 was less virulent than the parental strain, suggesting that in the context of the interplay among phage, bacterial pathogen and host, the emergence of phage resistance may be beneficial for the host.

1 March 2013 in Biological Control
Verified
Journal Article
Closed access
Gianandrea SalernoGianandrea Salerno
Gianandrea Salerno
FSFederica De Santis
Federica De Santis
AIAlessia Iacovone
Alessia Iacovone
FBFerdinando Bin
Ferdinando Bin
Eric ContiEric Conti
Eric Conti

28 November 2022 in Biomaterials
Verified
Journal Article
Closed access
MTMaria Tredicine
Maria Tredicine
FRFrancesco Ria
Francesco Ria
NPNoemi Poerio
Noemi Poerio
MLMatteo Lucchini
Matteo Lucchini
ABAssunta Bianco
Assunta Bianco
Gabriele Di SanteGabriele Di Sante
Gabriele Di Sante

1 January 2015 in Case Reports in Neurological Medicine
Verified
Journal Article
Open access
PDF file
FCFrancesca Crosta
Francesca Crosta
BOBerardino Orlandi
Berardino Orlandi
FSFederica De Santis
Federica De Santis
GPGianni Passalacqua
Gianni Passalacqua
JDJacopo C. DiFrancesco
Jacopo C. DiFrancesco
CMCarmine Marini
Carmine Marini
Background. Cerebral amyloid angiopathy-related inflammation (CAA-ri) results from autoimmune response to beta-amyloid deposits in cerebral vessels. Its clinical course and complications have seldom been described in literature.Case Report. In a patient presenting with delirium and left hemiparesis the diagnosis of CAA-ri was supported by the finding of elevated anti-amyloid autoantibodies in the cerebrospinal fluid (CSF). Steroid therapy produced significant improvements in clinical and investigational assessments, but after two months, it caused Acute Respiratory Distress Syndrome. After steroid therapy discontinuation the patient presented a rapidly progressive dementia, Guillain-Barré syndrome, new cerebral ischemic lesions, and thrombosis of the right cephalic and subclavian veins that were treated with subcutaneous heparin. After a week the patient died because of brain hemorrhage.Conclusion. This case suggests caution in steroid therapy discontinuation and antithrombotic therapy administration in patients with CAA-ri. The CSF search of anti-amyloid autoantibodies could be helpful to support the diagnosis.

15 August 2020 in Viruses
Verified
Journal Article
Open access
PDF file
PASQUALE MARMOPASQUALE MARMO
PASQUALE MARMO
MTMaria Cristina Thaller
Maria Cristina Thaller
GLGustavo Di Lallo
Gustavo Di Lallo
LALucia Henrici De Angelis
Lucia Henrici De Angelis
Noemi PoerioNoemi Poerio
Noemi Poerio
Marco Maria D'AndreaMarco Maria D'Andrea
Marco Maria D'Andrea
Members of Sphingomonas genus have gained a notable interest for their use in a wide range of biotechnological applications, ranging from bioremediation to the production of valuable compounds of industrial interest. To date, knowledge on phages targeting Sphingomonas spp. are still scarce. Here, we describe and characterize a lytic bacteriophage, named vB_StuS_MMDA13, able to infect the Sphingomonas turrisvirgatae MCT13 type strain. Physiological characterization demonstrated that vB_StuS_MMDA13 has a narrow host range, a long latency period, a low burst size, and it is overall stable to both temperature and pH variations. The phage has a double-stranded DNA genome of 63,743 bp, with 89 open reading frames arranged in two opposite arms separated by a 1186 bp non-coding region and shows a very low global similarity to any other known phages. Interestingly, vB_StuS_MMDA13 is endowed with an original nucleotide modification biosynthetic gene cluster, which greatly differs from those of its most closely related phages of the Nipunavirus genus. vB_StuS_MMDA13 is the first characterized lytic bacteriophage of the Siphoviridae family infecting members of the Sphingomonas genus.